Donor lymphocyte infusion

From Wikipedia, the free encyclopedia

Donor lymphocyte infusion (DLI) is a form of adoptive immunotherapy used after hematopoietic stem cell transplantation. Lymphocytes from the original stem cell donor are infused, after the transplant, to augment an anti-tumor immune response or ensure that the donor stem cells remain engrafted.[1][2] Complications of DLI include acute and chronic graft-versus-host disease and bone marrow aplasia, resulting in immunosuppression and susceptibility to opportunistic infections.[3]

[edit] Notes

  1. ^ Porter D, Levine JE (2006). "Graft-versus-host disease and graft-versus-leukemia after donor leukocyte infusion". Semin. Hematol. 43 (1): 53–61. doi:10.1053/j.seminhematol.2005.09.005. PMID 16412789. 
  2. ^ Loren AW, Porter DL (2006). "Donor leukocyte infusions after unrelated donor hematopoietic stem cell transplantation". Current opinion in oncology 18 (2): 107–14. doi:10.1097/01.cco.0000208781.61452.d3. PMID 16462177. 
  3. ^ Luznik L, Fuchs EJ (2002). "Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation". Cancer control : journal of the Moffitt Cancer Center 9 (2): 123–37. PMID 11965233. Full text

[edit] References

  • Thomas' Hematopoietic Cell Transplantation, ed. Blume KG, Forman SJ, Appelbaum FR. Blackwell Publishers, Cambridge, MA: 2004. ISBN 1-4051-1256-5.
 This oncology article is a stub. You can help Wikipedia by expanding it.